StockDrifts LogoStockDrifts

Kyungdong Pharmaceutical 011040

Company
경동제약Kyungdong Pharmaceutical
Insiders
4
Buys
27
Total Value
₩372M ($258K)
Avg Return
+1.60%
Last Filing
2026-07-13

Kyungdong Pharmaceutical (011040) has 27 disclosed insider purchases and 0 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩372M ($258K) in reported transaction value. The earliest filing StockDrifts holds for Kyungdong Pharmaceutical is dated 2024-01-11; the most recent is 2026-07-13. Across these filings the average return since disclosure is +1.60%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-14BUYMarket Buy
류 기 성
Ryu Ki-seong
CEO500₩5,120-1.9%₩3M ($2K)
2026-08-13BUYMarket Buy
류 기 성
Ryu Ki-seong
CEO1.9K₩5,140-2.3%₩10M ($7K)
2026-07-13BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman2.7K₩4,900+1.8%₩13M ($9K)
2026-07-07SELL증여
류 기 성
Ryu Ki-seong
CEO-300.0K₩4,995+0.1%₩1.5B ($1.1M)
2026-06-09BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman400---
2026-06-08BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman1.0K---
2026-06-04BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman91---
2026-02-26BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman1.0K---
2026-01-26BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman900₩5,760+4.7%₩5M ($4K)
2026-01-23BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman1.9K₩5,670+6.3%₩11M ($8K)
2025-10-30BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman5.0K₩5,720+5.4%₩29M ($20K)
2025-10-27BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman1.5K₩5,820+3.6%₩9M ($6K)
2025-10-24BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman660₩5,800+4.0%₩4M ($3K)
2025-09-08BUY자사주상여금
류 기 성
Ryu Ki-seong
CEO50---
2025-09-08BUY자사주상여금
류덕희
Ryu Deok-hee
Honorary Chairman50₩5,970+1.0%₩299K ($207)
2025-06-30BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman2.2K₩5,960+1.2%₩13M ($9K)
2025-06-27BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman7.7K₩5,990+0.7%₩46M ($32K)
2025-05-09BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman2.0K₩5,790+4.2%₩12M ($8K)
2025-05-08BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman3.0K₩5,830+3.4%₩17M ($12K)
2025-05-07BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman2.0K₩5,820+3.6%₩12M ($8K)
2025-04-04BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman1.0K₩5,530+9.0%₩6M ($4K)
2025-03-13BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman1.6K₩5,690+6.0%₩9M ($6K)
2025-03-12BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman40₩5,680+6.2%₩227K ($158)
2025-03-11BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman2.3K₩5,670+6.3%₩13M ($9K)
2025-01-01BUY신규선임
이근호
Lee Geun-ho
moving300₩6,180-2.4%₩2M ($1K)
2024-12-12BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman501₩6,030+0.0%₩3M ($2K)
2024-12-11BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman8.9K₩5,940+1.5%₩53M ($37K)
2024-12-10BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman900₩5,800+4.0%₩5M ($4K)
2024-11-14BUYMarket Buy
김석범
Seokbeom Kim
moving2.0K₩5,990+0.7%₩12M ($8K)
2024-07-15BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman7.5K₩6,840-11.8%₩51M ($36K)
2024-07-12BUYMarket Buy
류덕희
Ryu Deok-hee
Honorary Chairman2.3K₩6,890-12.5%₩16M ($11K)
2024-05-08BUYMarket Buy
김경훈
Kim Kyung-hoon
CEO3.0K₩6,350-5.0%₩19M ($13K)
2024-03-29BUY신규선임
박종식
Park Jong-sik
Outside Director25.0K₩6,490-7.1%₩162M ($113K)
2024-02-23BUYMarket Buy
이경묵
Lee Kyung-mook
moving2.2K₩6,450-6.5%₩14M ($10K)
2024-01-11BUY자사주상여금
김석범
Seokbeom Kim
moving500₩6,660-9.5%₩3M ($2K)
2024-01-11BUY자사주상여금
이경묵
Lee Kyung-mook
moving500₩6,660-9.5%₩3M ($2K)

Frequently asked questions

Who has been buying Kyungdong Pharmaceutical stock?
4 distinct insiders have filed 27 disclosed insider purchases in Kyungdong Pharmaceutical (011040), most recently on 2026-07-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Kyungdong Pharmaceutical have?
Kyungdong Pharmaceutical has 27 buy-side and 0 sell-side disclosures on record, covering ₩372M ($258K) in total reported value, spanning 2024-01-11 to 2026-07-13.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.